Lee Keene, Kim Seohyun, Zhao Junzhe, Neo Shi Yong
Department of Otolaryngology-Head and Neck Surgery, Stanford Cancer Institute, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, United States.
Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore.
Front Immunol. 2025 Aug 29;16:1631258. doi: 10.3389/fimmu.2025.1631258. eCollection 2025.
Viral etiologies of cancers have been widely studied for tumorigenesis and in recent years, widely recognized for their potential influence on immune regulation and response to immune checkpoint blockade (ICB). Here, we review the current understanding of how various oncogenic viruses are related to tumor immunogenicity and the tumor immune microenvironment. The present work also highlights the distinct features of these viral-driven cancers, that can be largely prognostic for better patient survival and response to ICB. On the other hand, there are also several commonalities in which these cancers acquire resistance against conventional immunotherapy. Finally, we discuss our perspectives to address the existing conundrums to gain clearer insights on how the interplay between anti-viral and anti-tumor immunity can be exploited to develop novel therapeutic interventions.
病毒致癌病因已被广泛研究用于肿瘤发生,近年来,其对免疫调节和免疫检查点阻断(ICB)反应的潜在影响也得到了广泛认可。在此,我们综述了目前对各种致癌病毒如何与肿瘤免疫原性和肿瘤免疫微环境相关的理解。本研究还强调了这些病毒驱动癌症的独特特征,这些特征在很大程度上可用于预测患者更好的生存和对ICB的反应。另一方面,这些癌症在获得对传统免疫疗法的抗性方面也存在一些共性。最后,我们讨论了我们的观点,以解决现有难题,从而更清楚地了解如何利用抗病毒免疫和抗肿瘤免疫之间的相互作用来开发新的治疗干预措施。